BACKGROUND: There is some evidence to suggest that one or two doses of the HPV vaccine provides similar protection to the three-dose regimen. The main aim of the study was to ascertain HPV-16/18 vaccine efficacy in both full and naive cohorts and to explore protection conferred against non-vaccine HPV types, by number of doses received. METHODS: Summary data from the Costa Rica Vaccine Trial (CVT; NCT00128661) and ~the PATRICIA trial (NCT001226810), two phase 3, double-blind, randomised controlled clinical trials of the HPV-16/18 AS04-adjuvanted vaccine in young women, were combined in a post-hoc analysis (GlaxoSmithKline [GSK] e-track number 202142) to investigate the efficacy of fewer than three doses of the HPV-16/18 vaccine after 4 years of follow-up. Women were randomly assigned to receive three doses of the HPV-16/18 vaccine or to a control vaccine; yet, some received fewer doses. After exclusion of women with less than 12 months of follow-up or those who were HPV-16/18 DNA-positive at enrolment (for the HPV-16/18 endpoint), we calculated vaccine efficacy against one-time detection of incident HPV infections after three, two, and one dose(s). The primary study endpoint was one-time detection of first incident HPV-16/18 infections accumulated during the follow-up phase. FINDINGS: We assessed vaccine efficacy against incident HPV-16/18 infection in the modified total vaccinated cohort (22 327 received three doses, 1185 two doses, 543 one dose). Vaccine efficacy against incident HPV-16/18 infections for three doses was 77·0% (95% CI 74·7-79·1), two doses was 76·0% (62·0-85·3), and one dose was 85·7% (70·7-93·7). Vaccine efficacy against incident HPV-31/33/45 infections for three doses was 59·7% (56·0-63·0), two doses was 37·7% (12·4-55·9), and one dose was 36·6% (-5·4 to 62·2). Vaccine efficacy against incident HPV-16/18 infection for two-dose women who received their second dose at 1 month was 75·3% (54·2-87·5) and 82·6% (42·3-96·1) for those who received the second dose at 6 months (CVT data only). Vaccine efficacy against HPV-31/33/45 for two-dose women who received their second dose at 6 months (68·1%, 27·0-87·0; CVT data only), but not those receiving it at one month (10·1%, -42·0 to 43·3), was similar to the three-dose group. INTERPRETATION: 4 years after vaccination of women aged 15-25 years, one and two doses of the HPV-16/18 vaccine seem to protect against cervical HPV-16/18 infections, similar to the protection provided by the three-dose schedule. Two doses separated by 6 months additionally provided some cross-protection. These data argue for a direct assessment of one-dose efficacy of the HPV-16/18 vaccine. FUNDING: US National Cancer Institute, National Institutes of Health Office of Research on Women's Health, and Ministry of Health of Costa Rica (CVT); GlaxoSmithKline Biologicals SA (PATRICIA).
RCT Entities:
BACKGROUND: There is some evidence to suggest that one or two doses of the HPV vaccine provides similar protection to the three-dose regimen. The main aim of the study was to ascertain HPV-16/18 vaccine efficacy in both full and naive cohorts and to explore protection conferred against non-vaccine HPV types, by number of doses received. METHODS: Summary data from the Costa Rica Vaccine Trial (CVT; NCT00128661) and ~the PATRICIA trial (NCT001226810), two phase 3, double-blind, randomised controlled clinical trials of the HPV-16/18 AS04-adjuvanted vaccine in young women, were combined in a post-hoc analysis (GlaxoSmithKline [GSK] e-track number 202142) to investigate the efficacy of fewer than three doses of the HPV-16/18 vaccine after 4 years of follow-up. Women were randomly assigned to receive three doses of the HPV-16/18 vaccine or to a control vaccine; yet, some received fewer doses. After exclusion of women with less than 12 months of follow-up or those who were HPV-16/18 DNA-positive at enrolment (for the HPV-16/18 endpoint), we calculated vaccine efficacy against one-time detection of incident HPV infections after three, two, and one dose(s). The primary study endpoint was one-time detection of first incident HPV-16/18 infections accumulated during the follow-up phase. FINDINGS: We assessed vaccine efficacy against incident HPV-16/18 infection in the modified total vaccinated cohort (22 327 received three doses, 1185 two doses, 543 one dose). Vaccine efficacy against incident HPV-16/18 infections for three doses was 77·0% (95% CI 74·7-79·1), two doses was 76·0% (62·0-85·3), and one dose was 85·7% (70·7-93·7). Vaccine efficacy against incident HPV-31/33/45 infections for three doses was 59·7% (56·0-63·0), two doses was 37·7% (12·4-55·9), and one dose was 36·6% (-5·4 to 62·2). Vaccine efficacy against incident HPV-16/18 infection for two-dose women who received their second dose at 1 month was 75·3% (54·2-87·5) and 82·6% (42·3-96·1) for those who received the second dose at 6 months (CVT data only). Vaccine efficacy against HPV-31/33/45 for two-dose women who received their second dose at 6 months (68·1%, 27·0-87·0; CVT data only), but not those receiving it at one month (10·1%, -42·0 to 43·3), was similar to the three-dose group. INTERPRETATION: 4 years after vaccination of women aged 15-25 years, one and two doses of the HPV-16/18 vaccine seem to protect against cervical HPV-16/18 infections, similar to the protection provided by the three-dose schedule. Two doses separated by 6 months additionally provided some cross-protection. These data argue for a direct assessment of one-dose efficacy of the HPV-16/18 vaccine. FUNDING: US National Cancer Institute, National Institutes of Health Office of Research on Women's Health, and Ministry of Health of Costa Rica (CVT); GlaxoSmithKline Biologicals SA (PATRICIA).
Authors: Aimée R Kreimer; Mark E Sherman; Vikrant V Sahasrabuddhe; Mahboobeh Safaeian Journal: J Natl Cancer Inst Date: 2015-02-02 Impact factor: 13.506
Authors: B Kleter; L J van Doorn; L Schrauwen; A Molijn; S Sastrowijoto; J ter Schegget; J Lindeman; B ter Harmsel; M Burger; W Quint Journal: J Clin Microbiol Date: 1999-08 Impact factor: 5.948
Authors: B Kleter; L J van Doorn; J ter Schegget; L Schrauwen; K van Krimpen; M Burger; B ter Harmsel; W Quint Journal: Am J Pathol Date: 1998-12 Impact factor: 4.307
Authors: Mahboobeh Safaeian; Carolina Porras; Yuanji Pan; Aimee Kreimer; John T Schiller; Paula Gonzalez; Douglas R Lowy; Sholom Wacholder; Mark Schiffman; Ana C Rodriguez; Rolando Herrero; Troy Kemp; Gloriana Shelton; Wim Quint; Leen-Jan van Doorn; Allan Hildesheim; Ligia A Pinto Journal: Cancer Prev Res (Phila) Date: 2013-11
Authors: Mark H Einstein; Peter Takacs; Archana Chatterjee; Rhoda S Sperling; Nahida Chakhtoura; Mark M Blatter; Jacob Lalezari; Marie-Pierre David; Lan Lin; Frank Struyf; Gary Dubin Journal: Hum Vaccin Immunother Date: 2014 Impact factor: 3.452
Authors: Sabrina H Tsang; Partha Basu; Noemi Bender; Rolando Herrero; Troy J Kemp; Aimée R Kreimer; Martin Müller; Gitika Panicker; Michael Pawlita; Ligia A Pinto; Joshua N Sampson; Rengaswamy Sankaranarayanan; John Schussler; Peter Sehr; Monica S Sierra; Elizabeth R Unger; Tim Waterboer; Allan Hildesheim Journal: Vaccine Date: 2020-07-24 Impact factor: 3.641
Authors: Molly A Feder; Shalini L Kulasingam; Nancy B Kiviat; Constance Mao; Erik J Nelson; Rachel L Winer; Hilary K Whitham; John Lin; Stephen E Hawes Journal: J Womens Health (Larchmt) Date: 2019-07-02 Impact factor: 2.681
Authors: Sabrina H Tsang; Joshua N Sampson; John Schussler; Carolina Porras; Sarah Wagner; Joseph Boland; Bernal Cortes; Douglas R Lowy; John T Schiller; Mark Schiffman; Troy J Kemp; Ana Cecilia Rodriguez; Wim Quint; Mitchell H Gail; Ligia A Pinto; Paula Gonzalez; Allan Hildesheim; Aimée R Kreimer; Rolando Herrero Journal: J Natl Cancer Inst Date: 2020-10-01 Impact factor: 13.506